Fedha

Hisa unazofuatilia
CSPCY:OTCMKTS
CSPC Pharmaceuticals Group ADR
US$ 5.03
0.00%
(0.00) Siku 1
6 Okt, 15:39:35 GMT -4  ·   USD
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya CSPCY...
Mtaji wa soko
105.43B
Wastani wa kiasi cha mauzo
elfu 1.61
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$ 5.46
Chini kwa wiki 52
US$ 3.26
Beta
0.37
Hisa za wawekezaji
2.88B
Idadi ya wafanyakazi
elfu 19
Mtaji wa soko
105.43B
Wastani wa kiasi cha mauzo
elfu 1.61
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$ 5.46
Chini kwa wiki 52
US$ 3.26
Beta
0.37
Hisa za wawekezaji
2.88B
Idadi ya wafanyakazi
elfu 19
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
Kuhusu CSPC Pharmaceuticals Group ADR
Afisa Mkuu Mtendaji (CEO)Zhang Cuilong
Wafanyakazielfu 18.6
Lilianzishwa1992
Makao makuu-
Sekta-
Ripoti za awaliThamani zote katika HKD
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika CNY
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
6.62B
6.11B
6.47B
12.13B
Gharama ya bidhaa zilizouzwa
2.28B
2.11B
2.20B
2.24B
Gharama ya mapato
2.28B
2.11B
2.20B
2.24B
Gharama za utafiti na maendeleo
1.50B
1.62B
1.40B
1.63B
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
1.97B
1.87B
1.89B
1.89B
Gharama ya uendeshaji
3.47B
3.49B
3.29B
3.51B
Jumla ya gharama za uendeshaji
5.75B
5.60B
5.49B
5.75B
Mapato ya uendeshaji
869.63M
514.71M
973.82M
6.38B
Mapato mengine yasiyo ya uendeshaji
645.14M
-470.42M
181.80M
11.92M
EBT ikijumuisha vipengee visivyo vya kawaida
1.18B
505.59M
1.13B
6.40B
EBT bila kujumuisha vipengee visivyo vya kawaida
1.37B
186.56M
1.13B
6.35B
Gharama ya kodi ya mapato
222.47M
165.64M
243.25M
825.70M
Kiwango cha kodi kinachotumika
18.78%
32.76%
21.46%
12.91%
Gharama nyingine za uendeshaji
-
-
-
-
Mapato halisi
963.54M
370.72M
859.79M
5.23B
Kiwango cha faida halisi
14.56%
6.06%
13.30%
43.16%
Mapato kwa kila hisa
-
-
-
-
Mapato ya riba na uwekezaji
-
195.87M
-
91.68M
Gharama ya riba
-104.94M
-6.76M
-11.01M
-2.30M
Jumla ya gharama halisi za riba
-104.94M
189.12M
-11.01M
89.37M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
1.14B
802.06M
1.26B
6.67B
Faida au hasara kutokana na uuzaji wa vipengee
-
-
-
-
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
Programu za Google